, Volume 233, Issue 13, pp 2571–2580 | Cite as

The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study

  • Josh D. Woolley
  • Peter A. Arcuni
  • Christopher S. Stauffer
  • Daniel Fulford
  • Dean S. Carson
  • Steve Batki
  • Sophia Vinogradov
Original Investigation



There has been an explosion of research on the potential benefits of the social neuropeptide oxytocin for a number of mental disorders including substance use disorders. Recent evidence suggests that intranasal oxytocin has both direct anti-addiction effects and pro-social effects that may facilitate engagement in psychosocial treatment for substance use disorders.


We aimed to assess the tolerability of intranasal oxytocin and its effects on heroin craving, implicit association with heroin and social perceptual ability in opioid-dependent patients receiving opioid replacement therapy (ORT) and healthy control participants.


We performed a randomized, double-blind, placebo-controlled, within- and between-subjects, crossover, proof-of-concept trial to examine the effects of oxytocin (40 international units) on a cue-induced craving task (ORT patients only), an Implicit Association Task (IAT), and two social perception tasks: the Reading the Mind in the Eyes Task (RMET) and The Awareness of Social Inference Test (TASIT).


Oxytocin was well tolerated by patients receiving ORT but had no significant effects on craving or IAT scores. There was a significant reduction in RMET performance after oxytocin administration versus placebo in the patient group only, and a significant reduction in TASIT performance after oxytocin in both the patient and healthy control groups.


A single dose of intranasal oxytocin is well tolerated by patients receiving ORT, paving the way for future investigations. Despite no significant improvement in craving or IAT scores after a single dose of oxytocin and some evidence that social perception was worsened, further investigation is required to determine the role oxytocin may play in the treatment of opioid use disorder.

Clinical Trial Registration

Methadone Oxytocin Option. identifier: NCT01728909


Oxytocin Heroin Opioid Addiction Tolerability Craving Implicit Social RMET Clinical 



This project was supported by the San Francisco Treatment Research Center at the University of California, San Francisco, via grant number P50 DA009253 from the National Institute on Drug Abuse.

Compliance with ethical standards

Conflict of interest

JDW, PAA, CSS, DF, SB, and SV have no conflicts of interest to report. DSC is a full-time employee of Trigemina, Inc. The opinions expressed here do not necessarily reflect the views or positions of Trigemina, Inc.


  1. Babor TF, Meyer RE, Mirin SM, Mcnamee HB, Davies M (1976) Behavioral and social effects of heroin self-administration and withdrawal. Arch Gen Psychiatry 33:363–367CrossRefPubMedGoogle Scholar
  2. Baron‐Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I (2001) The “Reading the Mind in the Eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 42:241–251CrossRefPubMedGoogle Scholar
  3. Bartz JA, Zaki J, Bolger N, Ochsner KN (2011) Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci 15(7):301–319Google Scholar
  4. Black Tar Heroin: The Dark End of the Street (1999) Directed by OKAZAKI, S. United States: Farallon FilmsGoogle Scholar
  5. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218CrossRefGoogle Scholar
  6. Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL, Kurian V, Ernst M, London ED (2002) Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 26(3):376–86CrossRefPubMedGoogle Scholar
  7. Bora E, Yücel M, Pantelis C (2009) Theory of mind impairment: a distinct trait-marker for schizophrenia spectrum disorders and bipolar disorder? Acta Psychiatr Scand 120:253–264CrossRefPubMedGoogle Scholar
  8. Carson DS, Guastella AJ, Taylor ER, Mcgregor IS (2013) A brief history of oxytocin and its role in modulating psychostimulant effects. J Psychopharmacol 27(3):231–247Google Scholar
  9. De Vries TJ, Shippenberg TS (2002) Neural systems underlying opiate addiction. J Neurosci 22:3321–3325PubMedGoogle Scholar
  10. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC (2007) Oxytocin improves “mind-reading” in humans. Biol Psychiatry 61:731–733CrossRefPubMedGoogle Scholar
  11. Fals-Stewart W, O’Farrell TJ, Freitas TT, Mcfarlin SK, Rutigliano P (2000) The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 68:134CrossRefPubMedGoogle Scholar
  12. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W (2010) Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 68:678–680CrossRefPubMedGoogle Scholar
  13. Gordon I, Martin C, Feldman R, Leckman JF (2011) Oxytocin and social motivation. Dev Cogn Neurosci 1:471–493CrossRefPubMedPubMedCentralGoogle Scholar
  14. Gossop M, Green L, Phillips G, Bradley B (1989) Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 154:348–353CrossRefPubMedGoogle Scholar
  15. Gossop M, Stewart D, Browne N, Marsden J (2002) Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 97:1259–1267CrossRefPubMedGoogle Scholar
  16. Greenwald AG, Poehlman TA, Uhlmann EL, Banaji MR (2009) Understanding and using the implicit association test: III. Meta-analysis of predictive validity. J Pers Soc Psychol 97:17CrossRefPubMedGoogle Scholar
  17. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS (2009) A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34:917–923CrossRefPubMedGoogle Scholar
  18. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB (2010) Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67:692–694CrossRefPubMedGoogle Scholar
  19. Haertzen CA, Hooks NT Jr (1969) Changes in personality and subjective experience associated with the chronic adminstration and withdrawal of opiates. J Nerv Ment Dis 148:606–614CrossRefPubMedGoogle Scholar
  20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The fagerstrom test for nicotine. Br J Addict 86:1119–27CrossRefPubMedGoogle Scholar
  21. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S (2007) Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61:498–503CrossRefPubMedGoogle Scholar
  22. Inturrisi CE, Verebely K (1971) Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 13:923–930CrossRefGoogle Scholar
  23. Jennings JR, Kamarck T, Stewart C, Eddy M, Johnson P (1992) Alternate cardiovascular baseline assessment techniques: vanilla or resting baseline. Psychophysiology 29:742–50CrossRefPubMedGoogle Scholar
  24. Kelly JF, Magill M, Stout RL (2009) How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in Alcoholics Anonymous. Addict Res Theory 17:236–259CrossRefGoogle Scholar
  25. Knight DK, Simpson DD (1996) Influences of family and friends on client progress during drug abuse treatment. J Subst Abus 8:417–429CrossRefGoogle Scholar
  26. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58CrossRefPubMedGoogle Scholar
  27. Kornreich C, Foisy M-L, Philippot P, Dan B, Tecco J, Noël X, Hess U, Pelc I, Verbanck P (2003) Impaired emotional facial expression recognition in alcoholics, opiate dependence subjects, methadone maintained subjects and mixed alcohol-opiate antecedents subjects compared with normal controls. Psychiatry Res 119:251–260CrossRefPubMedGoogle Scholar
  28. Kovács G, Horváth Z, Sarnyai Z, Faludi M, Telegdy G (1985a) Oxytocin and a C-terminal derivative (Z-prolyl-D-leucine) attenuate tolerance to and dependence on morphine and interact with dopaminergic neurotransmission in the mouse brain. Neuropharmacology 24:413–419CrossRefPubMedGoogle Scholar
  29. Kovács GL, Borthaiser Z, Telegdy G (1985b) Oxytocin reduces intravenous heroin self-administration in heroin-tolerant rats. Life Sci 37:17–26CrossRefPubMedGoogle Scholar
  30. Kovacs GL, Vecsernyes M, Laczi F, Faludi M, Telegdy G, Laszlo FA (1985) Acute morphine treatment and morphine tolerance/dependence alter immunoreactive oxytocin levels in the mouse hippocampus. Brain Res 328:158–60CrossRefPubMedGoogle Scholar
  31. Kovács GL, Sarnyai Z, Szabó G (1998) Oxytocin and addiction: a review. Psychoneuroendocrinology 23:945–962CrossRefPubMedGoogle Scholar
  32. Kriván M, Szabó G, Sarnyai Z, Kovács GL, Telegdy G (1992) Oxytocin blocks the development of heroin-enkephalin cross-tolerance in mice. Pharmacol Biochem Behav 43:187–192CrossRefPubMedGoogle Scholar
  33. Lane KA, Banaji MR, Nosek BA, Greenwald AG (2007) Understanding and using the implicit association test: IV. In: Wittenbrink B, Schwarz N (eds) Implicit measures of attitudes. New York, The Guilford Press, pp 59–102Google Scholar
  34. Lee MR, Glassman M, King-Casas B, Kelly DL, Stein EA, Schroeder J, Salmeron BJ (2014) Complexity of oxytocin׳ s effects in a chronic cocaine dependent population. Eur Neuropsychopharmacol 24:1483–1491Google Scholar
  35. Lindgren KP, Neighbors C, Westgate E, Salemink E (2014) Self-control and implicit drinking identity as predictors of alcohol consumption, problems, and cravings. J Stud Alcohol Drugs 75:290Google Scholar
  36. Liu Y, Aragona BJ, Young KA, Dietz DM, Kabbaj M, Mazei-Robison M, Nestler EJ, Wang Z (2010) Nucleus accumbens dopamine mediates amphetamine-induced impairment of social bonding in a monogamous rodent species. Proc Natl Acad Sci 107:1217–1222CrossRefPubMedGoogle Scholar
  37. Macdonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ (2011) A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 36:1114–1126CrossRefPubMedGoogle Scholar
  38. Marhe R, Waters AJ, Van De Wetering BJM, Franken IHA (2013) Implicit and explicit drug-related cognitions during detoxification treatment are associated with drug relapse: an ecological momentary assessment study. J Consult Clin Psychol 81:1CrossRefPubMedGoogle Scholar
  39. Mcgregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long‐term adverse consequences of drug use? Br J Pharmacol 154:358–368Google Scholar
  40. Mcrae-Clark AL, Baker NL, Moran-Santa Maria M, Brady KT (2013) Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology 228:623–631CrossRefPubMedPubMedCentralGoogle Scholar
  41. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12:524–538CrossRefPubMedGoogle Scholar
  42. Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SMR, Tajdini M, Ghaleiha A, Akhondzadeh S (2013) Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia. CNS Drugs 27:57–65CrossRefPubMedGoogle Scholar
  43. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR (1987) Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 96:122CrossRefPubMedGoogle Scholar
  44. Mueller SE, Degen B, Petitjean S, Wiesbeck GA, Walter M (2009) Gender differences in interpersonal problems of alcohol-dependent patients and healthy controls. Int J Environ Res Public Health 6:3010–3022CrossRefPubMedPubMedCentralGoogle Scholar
  45. Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, Landgraf R (2013) Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology 38:1985–1993CrossRefPubMedGoogle Scholar
  46. NIDA 2012. Mental Health Services Administration (2012) Results from the 2011 national survey on drug use and health: summary of national findings. NSDUH Series H-44, HHS Publication No (SMA), 12–4713Google Scholar
  47. Norman GJ, Cacioppo JT, Morris JS, Karelina K, Malarkey WB, Devries AC, Berntson GG (2011) Selective influences of oxytocin on the evaluative processing of social stimuli. J Psychopharmacol 25(10):1313–1319Google Scholar
  48. Pedersen CA, Boccia ML, Kampov-Polevoi A (2011) Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders. Google PatentsGoogle Scholar
  49. Pedersen CA, Smedley KL, Leserman J, Jarskog LF, Rau SW, Kampov‐Polevoi A, Casey RL, Fender T, Garbutt JC (2013) Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res 37:484–489CrossRefPubMedGoogle Scholar
  50. Radke S, De Bruijn ERA (2015) Does oxytocin affect mind-reading? A replication study. Psychoneuroendocrinology 60:75–81CrossRefPubMedGoogle Scholar
  51. Raisch DW, Fye CL, Boardman KD, Sather MR (2002) Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 36:312–321CrossRefPubMedGoogle Scholar
  52. Robinson TE, Berridge KC (2001) Incentive-sensitization and addiction. Addiction 96:103–114CrossRefPubMedGoogle Scholar
  53. Sarnyai Z, Kovács GL (1994) Role of oxytocin in the neuroadaptation to drugs of abuse. Psychoneuroendocrinology 19:85–117CrossRefPubMedGoogle Scholar
  54. Sarnyai Z, Kovács GL (2014) Oxytocin in learning and addiction: from early discoveries to the present. Pharmacol Biochem Behav 119:3–9CrossRefPubMedGoogle Scholar
  55. Schulteis G, Ahmed SH, Morse AC, Koob GF, Everitt BJ (2000) Conditioning and opiate withdrawal. Nature 405:1013–4CrossRefPubMedGoogle Scholar
  56. Shany-Ur T, Poorzand P, Grossman SN, Growdon ME, Jang JY, Ketelle RS, Miller BL, Rankin KP (2012) Comprehension of insincere communication in neurodegenerative disease: lies, sarcasm, and theory of mind. Cortex 48:1329–1341CrossRefPubMedGoogle Scholar
  57. Shi J, Zhao L-Y, Copersino ML, Fang Y-X, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L (2008) PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 579:160–166CrossRefPubMedGoogle Scholar
  58. Stein DJ, Van Honk J, Ipser J, Solms M, Panksepp J (2007) Opioids: from physical pain to the pain of social isolation. CNS Spectr 12:669–674CrossRefPubMedGoogle Scholar
  59. Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154:230–242CrossRefPubMedGoogle Scholar
  60. Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W, Hurlemann R (2013) Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep 3:3440CrossRefPubMedPubMedCentralGoogle Scholar
  61. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ (2010) A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 30:155–166CrossRefPubMedGoogle Scholar
  62. Woolley JD, Chuang B, Lam O, Lai W, O’Donovan A, Rankin KP, Mathalon DH, Vinogradov S (2014) Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 47:116–25CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg (outside the USA) 2016

Authors and Affiliations

  • Josh D. Woolley
    • 1
    • 2
  • Peter A. Arcuni
    • 2
  • Christopher S. Stauffer
    • 1
    • 2
  • Daniel Fulford
    • 3
  • Dean S. Carson
    • 4
  • Steve Batki
    • 1
    • 2
  • Sophia Vinogradov
    • 1
    • 2
  1. 1.Department of PsychiatryUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Department of Mental HealthSan Francisco Veterans Affairs Medical CenterSan FranciscoUSA
  3. 3.Sargent College of Health & Rehabilitation SciencesBoston UniversityBostonUSA
  4. 4.Department of Psychiatry and Behavioral SciencesStanford University School of MedicineStandfordUSA

Personalised recommendations